API Fevipiprant NVP - QAW039 Anti Estrogen Steroids CAS 872365-14-5

Place of Origin China
Brand Name XRD
Certification GMP
Model Number 872365-14-5
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time 1-2days after payment received
Payment Terms T/T bank, Western Union, Bitcoin, Etc
Supply Ability 100KG/ Month

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

x
Product Details
CAS 872365-14-5 Product Name Fevipiprant
Type Anti-hair Loss Powder Appearance White Powder
Usage Anti-hair Loss Powder Alias Fevipiprant
Assay 99% Key Words Fevipiprant
High Light

anti estrogen steroids

,

hair growing powder

Leave a Message
Product Description

Anti-hair Loss Powder API Fevipiprant(NVP-QAW039) Fevipiprant CAS 872365-14-5

 

 

Quick Details

 

Name Formestane
CAS No. 566-48-3
EINECS N/A
MF C19H26O3
MW 302.41
MP 199-202°C
Storage temp. 2-8°C
Purity 99% min
Usage An antitumor drug. An aromatase inhibitor
Appearance Needles

Formestane also is known as lentaron,is an anti-cancer drug, it is primarily used for the treatment of postmenopausal women with advanced breast cancer, it is also effective in prostate cancer

 

 

Introduction:

 

1) Product Name:Supply Anti-hair Fevipiprant powder CAS 872365-14-5

2) Purity: ≥99%
3) Appearance: White fine powder
4) Introduction:

Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3
As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]

 

Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

 

 

API Fevipiprant NVP - QAW039 Anti Estrogen Steroids CAS 872365-14-5 0

 

 

API Fevipiprant NVP - QAW039 Anti Estrogen Steroids CAS 872365-14-5 1

 

 

 

 

Anti-hair Loss Powder API Fevipiprant(NVP-QAW039) Fevipiprant CAS 872365-14-5